Introduction {#s1}
============

Demyelination, a hallmark of many central nervous system (CNS) diseases, is a main cause of neurological dysfunction. Improved remyelination is of potential interest in driving therapeutic manipulation, but drugs which mediate a fundamental cure for CNS demyelination diseases are not clinically available and are greatly needed. Remyelination is mediated by oligodendrocyte precursor cells (OPCs), which are distributed throughout the adult mammalian CNS ([@bib6]). Successful remyelination requires OPC proliferation, migration, differentiation to oligodendrocytes, and finally, maturation into myelinating oligodendrocytes ([@bib10]). The last of these processes is essential for the structural repair and functional integrity of neuronal networks in the CNS.

Remyelination occurs as a spontaneous and efficient process in experimental models and many clinical conditions ([@bib9]). Because remyelination is controlled by environmental signals ([@bib4]), OPCs and oligodendrocytes around demyelinated lesions are thought to receive the signals which promote maturation. With respect to the molecular mechanism, it is believed that oligodendrocyte maturation is controlled by the CNS-cell-derived factors, such as axonal F3-mediated Notch signaling ([@bib13]), and astrocyte-derived leukemia inhibitory factor ([@bib8]). In contrast, demyelination often occurs simultaneously with vascular damage ([@bib31]) and vascular damage leads to leakage of circulating factors into the CNS, suggesting that oligodendrocytes around the demyelinating lesion are exposed to circulating factors. In support of this idea, circulating FGF21 leaks into the CNS after injury and promotes OPC proliferation ([@bib21]), a first step in remyelination. Although previous findings established the concept that successful remyelination requires oligodendrocyte maturation, the mechanism by which the circulating factors regulates oligodendrocyte maturation remains unknown.

TGF-βs are members of a superfamily of multifunctional cytokines with key functions in development, patterning, and immune responses. In CNS pathology, TGF-βs have implications in inflammatory responses through the activation of microglia in a number of animal models of diseases including stroke ([@bib15]), Alzheimer disease (AD) ([@bib40]), and multiple sclerosis (MS) ([@bib1]). These observations are in line with the concept that TGF-βs are produced by the CNS and effect physiological reactions in neighboring cells, resulting in the progress of disease severity. However, in experimental autoimmune encephalomyelitis (EAE), systemic administration of TGF-β1 prevents disease severity ([@bib22]). Moreover, the levels of TGF-β1 in serum obtained from the patients with amnestic mild cognitive impairment is low when compared with control patients, and this change is positively correlated with cognitive performance ([@bib14]). Because TGF-β is known to control the timing of remyelination ([@bib30]), we hypothesized that circulating TGF-β1 may have a protective role in the CNS and may specifically promote remyelination.

In this study, we showed that TGF-β1, which is largely expressed in the peripheral environments, promoted oligodendrocyte maturation in mice spinal cord which were subjected to toxin-induced demyelination. Decrease in circulating TGF-β1 levels prevented spontaneous remyelination. Systemic administration of TGF-β1 promoted remyelination and decreased disease severity in EAE. TGF-β1 treatment promoted expression of myelin-associated gene in human oligodendrocyte in culture. These data suggest that the administration of systemic TGF-β1 may provide a therapeutic avenue for demyelinating diseases.

Results {#s2}
=======

TGF-β1 in adult mouse serum facilities oligodendrocyte maturation in vitro {#s2-1}
--------------------------------------------------------------------------

We first investigated the possibility that circulating factors promote oligodendrocyte maturation. To test this, we performed an in vitro analysis to determine if treatment with adult mouse serum enhances the expression of myelin basic protein (MBP) in Olig2-positive oligodendrocyte lineages cells using high-content imaging analysis (HCA; [Figure 1A](#fig1){ref-type="fig"}). Adult mouse serum treatment promoted MBP expression in oligodendrocyte-lineage cells ([Figure 1B,C](#fig1){ref-type="fig"}), indicating that adult serum contains factors involved in the promotion of oligodendrocyte maturation. The MBP expression activity was not abolished by the pre-treatment of serum with DNase, RNase, and heat shock ([Figure 1---figure supplement 1A--D](#fig1s1){ref-type="fig"}), suggesting that the factor(s) in the adult mouse serum which may be involved in oligodendrocyte maturation may comprise peptides and have the property of being heat-resistant.

![TGF-β1 drives oligodendrocyte maturation.\
(**A**) (Upper panels) Representative images of the oligodendrocyte cultures. Cells were stained with MBP (green) and Olig2 (magenta). (Lower panels) Yellow outlines were obtained from HCA to measure the MBP-positive area in Olig2-positive cells. (**B**) Representative images of the culture stained with MBP and Olig2. Cells were cultured 5 days after the adult mice serum treatment. (**C**) Quantification of MBP-positive area in Olig2-positive cells indicated in B (n = 8 for each), p=0.0009. (**D**) Representative images of culture stained with MBP and Olig2. Cells were treated with 1 μM of LY364847 (a TGF-βRI inhibitor), and then with adult mice serum. (**E**) Quantification of MBP-positive area in Olig2-positive cells indicated in D (n = 6 for each), p=0.0111, 0.0195 (left to right). (**F**) Representative images of oligodendrocyte stained with MBP and Olig2. Cells were transfected with TGF-β RI siRNA and treated with serum. (**G**) Quantification of MBP-positive area in Olig2-positive cells indicated in F (n = 5 for each), p=0.0011, 0.0104 (left to right). (**H**) Representative images of culture stained with MBP and Olig2. Cells were cultured with the indicated concentration of recombinant TGF-β1. (**I**) Quantification of MBP-positive area in Olig2-positive cells indicated in H (n = 3 for each), p=0.0007, 0.003 (left to right). (**J**) Representative image of TGF-βRI expression in the culture. Arrowheads indicate cells co-labeled with TGF-βRI (green) and APC (magenta). \*\*p\<0.01, \*p\<0.05, Student's *t*-test or ANOVA with Tukey's post-hoc test. Error bars represent SEM. Scale bars represent 20 μm for J, 100 μm for others.\
10.7554/eLife.41869.004Figure 1---source data 1.Pharmacological impact for serum-mediated oligodendrocyte maturation.Inhibitors were used at a final concentration of 10 μM. Each line shows the relative values of MBP/Olig2 area (two rows from the left) and Olig2 cell number (two rows from the right) relative to the control value (DMSO treatment without serum). TGF-βRI kinase inhibitor (red letters) is the only drug we tested that targets a receptor-type protein. The data is average of two trials.](elife-41869-fig1){#fig1}

To investigate the molecular mechanism of adult mouse serum-mediated oligodendrocyte maturation, we conducted pharmacological screening (as described in Materials and methods). We first selected drugs that did not inhibit cell survival by counting the number of Olig2-positive cells. Of 160 drugs, 107 drugs did not decrease of the abundance of Olig2-positive cells (0.5 times lower than control) in the culture after each treatment. Next, we excluded the drugs that decreased MBP expression (0.5 times lower than control) in the cells by drugs treatment with or without serum, and identified 17 drugs that caused downregulation of MBP area (two times lower than control) relative to serum treatment ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Because we hypothesized that a circulating molecule drives oligodendrocyte maturation directly, we focused on the TGF-β receptor type I inhibitor (TGF-βRI), the only drug we tested that specifically targets a receptor-type protein. To investigate the role of TGF-βRI in serum-mediated oligodendrocyte maturation, we used LY-364947, a TGF-β type I receptor (TGF-βRI) kinase inhibitor and found that it blocked serum-promoted oligodendrocyte maturation ([Figure 1D,E](#fig1){ref-type="fig"}). We also confirmed that transfection of oligodendrocytes with TGF-βRI siRNA diminished serum-mediated maturation ([Figure 1F,G](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Since TGF-β is known as heat stable protein ([@bib32]), we wondered whether TGF-β in serum binds oligodendrocytes directly, resulting in the promotion of oligodendrocyte maturation. We observed that oligodendrocyte treated with recombinant mouse TGF-β1 showed increased maturation ([Figure 1H,I](#fig1){ref-type="fig"}). Immunocytochemical analysis revealed that adenomatous polyposis coli (APC)-labeled cells in the oligodendrocyte culture expressed TGF-βRI ([Figure 1J](#fig1){ref-type="fig"}). Western blot analysis revealed that treatment with TGF-β enhanced Smad2 phosphorylation in the oligodendrocyte culture ([Figure 1---figure supplement 1F,G](#fig1s1){ref-type="fig"}). These data suggest that TGF-β in adult mouse enhances oligodendrocyte maturation directly.

Circulating TGF-β1 contributes to remyelination in the CNS {#s2-2}
----------------------------------------------------------

To determine the effect of TGF-β1 in vivo, we investigated the expression pattern of TGF-β1 in adult mice. Quantitative protein analysis revealed that there was appreciable TGF-β1 expression in the spleen ([Figure 2A](#fig2){ref-type="fig"}), which is correlated with the high concentration of circulating TGF-β1 compared with concentrations in cerebrospinal fluid (CSF) (Serum, 143361.3 ± 18715.5 pg/ml; CSF, 33.4 ± 10.1 pg/ml, [Figure 2B](#fig2){ref-type="fig"}). To investigate the contribution of peripheral TGF-β1 in CNS remyelination, we used a lysophosphatidylcholine (LPC)-induced demyelination model which accompanied by a vascular barrier disruption around the lesion site ([@bib27]). In this model, we detected high levels of TGF-β1 around the LPC lesion in the CNS ([Figure 2C](#fig2){ref-type="fig"}) without any change in levels of circulating TGF-β1 after LPC injection ([Figure 2D](#fig2){ref-type="fig"}). These data support the possibility that circulating TGF-β1 accumulates in CNS lesions.

![TGF-β1 level in circulation is higher than that in the CNS.\
(**A**) Quantification of TGF-β1 protein level in individual organs in intact mice (n = 3 for each), p\<0.0001. (**B**) Quantification of TGF-β1 protein concentration in the serum and CSF (n = 3 for serum, n = 4 for CSF), p=0.0007. (**C**) Representative image of spinal cord section which is labeled with TGF-β1. The spinal cord sections were obtained 7 days after LPC injection. (**D**) Quantification of TGF-β1 protein concentration in the serum 7 days after LPC injection (n = 3 for each). NS indicates not significant difference. \*\*p\<0.01, Student's *t*-test or ANOVA with Tukey's post-hoc test. Error bars represent SEM. Scale bars represent 100 μm.](elife-41869-fig2){#fig2}

We next investigated whether influx of circulating TGF-β1 into the CNS contributes to the process of remyelination. To analyze the role of circulating TGF-β1 on CNS remyelination, we depleted platelets by injecting anti-CD41 monoclonal antibodies (mAbs) ([@bib29]), as circulating TGF-β1 is transported by platelets ([@bib11]) [Figure 3A](#fig3){ref-type="fig"}). Platelet depletion reduced the TGF-β1 level in the spleen ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) and the fluorescence intensity of TGF-β1 at the LPC lesion ([Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}). We then asked whether a decrease in circulating TGF-β1 level prevents remyelination after LPC injection. Mice, which had registered demyelination immediately after LPC injection, exhibited significant remyelination within 2 weeks post-injection ([@bib33]); therefore, the decrease in the area lacking MBP expression in the spinal cord 2 weeks after LPC injection indicates the success of remyelination ([@bib21]). Immunohistochemical analysis revealed that mice that had received anti-CD41 mAb had a larger MBP-negative area than control mice ([Figure 3B,C](#fig3){ref-type="fig"}), indicating that platelet depletion inhibited remyelination. Myelin formation in the intact spinal cord was not changed after anti-CD41 mAb administration ([Figure 3---figure supplement 1D,E](#fig3s1){ref-type="fig"}). Electron microscopic analysis revealed that the thickness of myelin sheaths was significantly lower in mice treated with anti-CD41 mAb than in controls ([Figure 3D,E](#fig3){ref-type="fig"}), indicating that our immunohistological observations were consistent with the promotion of structural remyelination. We then asked whether TGF-β1 makes a major contribution to circulating factor-mediated remyelination. We used neutralizing TGF-β antibodies ([@bib5]; [@bib2]); [@bib38]) and intraperitoneally administrated the antibodies into the mice every 2 days from 7 days after LPC injection. Mice injected with neutralizing TGF-β antibodies had a larger MBP-negative area around the LPC lesion than controls ([Figure 3F,G](#fig3){ref-type="fig"}), and the inhibition of remyelination following TGF-β neutralization was comparable to the level observed in platelet-depletion experiments (*Pint* = 0.6126, single regression analysis). These data indicate that spontaneous remyelination depends on circulating TGF-β1.

![Circulating TGF-β1 supports spontaneous remyelination.\
(**A**) Quantification of circulating TGF-β1 level in the mice with platelet depletion. Plasma from mice were obtained from 7 days after the start of anti-CD41 mAbs injection (n = 7 for control IgG, n = 8 for anti-CD41 mAbs), p=0.0001. (**B**) Representative images of spinal cord sections labeled for MBP. Spinal cords were dissected from mice 14 days after LPC injection. (**C**) Quantification of an MBP-negative area in the dorsal column of spinal cord as indicated in B (n = 9 for each), p=0.0347. (**D**) Representative electron micrographs of myelin in the spinal cord. Sections were obtained from mice treated with anti-CD41 mAb 14 days after LPC injection. (**E**) Graphs show quantitation of the g-ratio indicated in D (n = 4 for each), p=0.0347. (**F**) Representative images of spinal cord sections labeled for MBP. Spinal cords were obtained 14 days after LPC injection. Injection of TGF-β neutralizing antibodies was started 7 days after LPC and continued every other day (n = 7), p=0.0278. (**G**) Quantification of an MBP-negative area in the dorsal column of spinal cord, as indicated in F. NS indicates not significant difference. \*\*p\<0.01, \*p\<0.05, Student's *t*-test. Error bars represent SEM. Scale bars represent 100 μm for B, F, 2 μm for D.](elife-41869-fig3){#fig3}

TGF-βRI in oligodendrocytes is involved in spontaneous remyelination {#s2-3}
--------------------------------------------------------------------

Because we detected high level of TGF-βRI expression in APC-labeled oligodendrocytes compared with that in platelet-derived growth factor alpha (PDGFRα)-labeled oligodendrocyte precursor cells ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), we hypothesized that circulating TGF-β1 acts directly on oligodendrocytes resulting in the promotion of remyelination. To investigate this, we generated inducible, oligodendrocyte-specific TGF-βRI knockout mice by using Plp-creER^T^: TGF-βRI floxed mice, which allowed tamoxifen-inducible deletion of TGF-βRI expression in oligodendrocytes ([Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}). Histological analysis revealed that the conditional compared with the control littermates, knockout mice had a larger MBP-negative area in the dorsal spinal cord ([Figure 4B,C](#fig4){ref-type="fig"}). LPC injection into the spinal cord caused motor deficits, which, however, improved over time due to spontaneous remyelination ([@bib12]). We then asked whether TGF-βRI signaling is required for motor recovery after LPC injection. By behavioral analysis, significant inhibition of motor recovery was detected in the conditional knockout mice than in the control mice ([Figure 4D](#fig4){ref-type="fig"}). TGF-β1 treatment did not change the MBP-negative area in the oligodendrocyte-specific TGF-βRI knockout mice 2 weeks after LPC injection ([Figure 4E,F](#fig4){ref-type="fig"}). There was no significant difference in MBP-positive area in oligodendrocyte-specific TGF-βRI knockout mice that did not receive LPC injection ([Figure 4---figure supplement 1D,E](#fig4s1){ref-type="fig"}). These data indicate that direct interaction of circulating factors with CNS oligodendrocytes mediates spontaneous remyelination.

![TGF-βRI in oligodendrocytes is required for remyelination.\
(**A**) Representative images of spinal cord sections double-labeled for APC and TGF-βRI. Spinal cords were obtained from control mice. The white arrowheads show APC^+^ TGF-βRI^+^ cells. (**B**) Representative images of spinal cord sections labeled for MBP. Spinal cords were obtained from the tamoxifen-treated conditional knockout mice 14 days after LPC injection. Control data was obtained from the conditional knockout mice without tamoxifen treatment. (**C**) Quantification of MBP-negative area in the dorsal column of spinal cord as indicated in B (n = 10 for control, n = 8 for conditional knockout mice), p=0.0364. (**D**) Motor function was assessed by beam walk test (n = 10 for each), p=0.0156. (E) Representative images of spinal cord sections labeled for MBP. Spinal cords were obtained from tamoxifen-treated conditional knockout mice 14 days after LPC injection. Data were obtained from conditional knockout mice with or without recombinant TGF-β1 treatment. (F) Quantification of MBP-negative area in the dorsal column of spinal cord, as indicated in D (n = 3 for each; p=0.4816). (**F**) \*p\<0.05, Student's *t*-test or Two-way ANOVA with Bonferroni's post-hoc test. Error bars represent SEM. Scale bars represent 20 μm for A, and 100 μm for B and D.](elife-41869-fig4){#fig4}

TGF-β administration promotes CNS remyelination {#s2-4}
-----------------------------------------------

To address whether TGF-β1 is sufficient to cause circulating-factor-mediated remyelination, we examined increase of remyelination efficiency by exogenous TGF-β1 administration in mice which did not show severe vascular barrier disruption. In the cuprizone feeding demyelination model, spontaneous remyelination occurs after terminating the administration of cuprizone; however, the remyelination efficiency is known to be lower when compared with the vascular barrier disruption demyelination model ([@bib21]). Therefore, we asked whether intracerebroventricular infusion of TGF-β1 could promote remyelination after cuprizone diet. Histological analysis revealed that the MBP-negative area was smaller in the corpus callosum of mice administered with TGF-β1 than of control animals ([Figure 5A,B](#fig5){ref-type="fig"}). These data support the fact that exogenous TGF-β1 administration mimics remyelination with the same efficiency as that driven by circulating factors.

![TGF-β1 treatment promotes remyelination.\
(**A**) Representative image of brain section labeled for MBP. Brains were obtained from the cuprizone fed mice, along with TGF-β1 administration for 14 days after removal of cuprizone diet. (**B**) Quantification of MBP-negative area in the corpus callosum as indicated in A (n = 7 for control, n = 8 for TGF-β1), p=0.0444. (**C**) Representative image of spinal cord section labeled for MBP. Spinal cords were dissected from the mice 25 days after EAE induction. Right panels show high magnification of left panels. (**D**) Quantification of MBP-negative area in the spinal cord as indicated in C (n = 7 for each), p=0.0125. (**E**) EAE score of the mice with TGF-β1 administration. TGF-β1 administration was started 15 days after EAE induction and continued daily injection at the end of period (n = 13 for control, n = 12 for TGF-β1), p=0.049. (**F**) Relative intensity of fluorescent dye-labeled recombinant mouse TGF-β1 in the spinal cord obtained from EAE mice (n = 6 for control, n = 5 for EAE), p=0.0193. (**G**) Representative image of spinal cord section from EAE mice. EAE mice received fluorescent-dye-labeled recombinant mouse TGF-β1. \*p\<0.05, Student's *t*-test or two-way ANOVA with Bonferroni's post-hoc test. Error bars represent SEM. Scale bars represent 100 μm.](elife-41869-fig5){#fig5}

We then sought to determine the therapeutic potential of our results described above. Myelin oligodendrocyte glycoprotein (MOG) ~35-55~-induced EAE model is relatively controlled and shows demyelination pathology of MS ([@bib28]). We started TGF-β1 administration at the peak of the clinical score (day 15) in EAE and continued administration during the observation period. TGF-β1-treated mice showed restoration of MBP expression in the spinal cord, whereas vehicle-treated mice showed sustained areas of white matter disruption ([Figure 5C,D](#fig5){ref-type="fig"}). By contrast, we observed no change in the accumulation of inflammatory cells ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}), cytokine release ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), or cell proliferation ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}), indicating that TGF-β1-mediated remyelination does not depend on regulation of immunological responses. Consistent with these histological changes, behavioral evaluation showed that TGF-β1 administration starting 15 days after immunization improved neurological function significantly ([Figure 5E](#fig5){ref-type="fig"}). We also detected an intravenously injected fluorescently-labeled TGF-β1 in spinal cord tissues indicating that circulating TGF-β1 leaks into the CNS in EAE ([Figure 5F,G](#fig5){ref-type="fig"}). These data suggest that enhancement of circulating-factor activity is useful in treating demyelination.

TGF-β enhanced human oligodendrocyte maturation {#s2-5}
-----------------------------------------------

We then determined if our findings in mouse studies were translatable to humans. Immunohistochemical analysis of autopsy samples from MS patients revealed TGF-βRI expression in APC-positive oligodendrocytes ([Figure 6A](#fig6){ref-type="fig"}). We also investigated whether TGF-β1 would promote oligodendrocyte maturation in human samples. For this purpose, we used commercially available OPC cultures established from human embryonic stem cells and treated the cells with recombinant human TGF-β1. Real-time PCR analysis revealed that treatment with recombinant human TGF-β1 increased the levels of mRNAs encoding myelin-associated proteins (MBP, MAG, and PLP) in human oligodendrocyte cultures in vitro ([Figure 6B](#fig6){ref-type="fig"}), implying that TGF-β1--mediated oligodendrocyte maturation could also occur in humans.

![TGF-β1 stimulates human oligodendrocyte maturation.\
(**A**) Representative images of spinal cord sections double-labeled for APC with TGF-βRI. Brain samples were obtained post-mortem from MS patients. (**B**) Relative expression of indicated mRNA in human oligodendrocyte. The cells were treated with recombinant human TGF-β1 (10 nM) for 3 days (n = 9 for each), p*=*0.0278 (*MBP*), 0.0222 (*MAG*), 0.0001 (*PLP*). \*\*p\<0.01, \*p\<0.05, Student's *t*-test. Error bars represent SEM. Scale bar represents 50 μm.](elife-41869-fig6){#fig6}

Discussion {#s3}
==========

The CNS is isolated from the peripheral environment under normal physiological conditions by the presence of vascular barrier, but this barrier is impaired in several types of diseases including AD, dementia, traumatic brain injury, and MS. Because disruption of the vascular barrier leads to hypoperfusion and causes excessive inflammatory response in acute CNS injury ([@bib41]), vascular impairment is increasingly thought to be associated with disturbances in CNS homeostasis. In contrast, chronic demyelinating lesions are characterized by less damage of blood brain barrier (BBB) when compared with the damage caused by an active lesion ([@bib20]; [@bib24]). Consistent with this, an area of chronic demyelination that fails to undergo remyelination is considered to arise due to the decline of maturation activity in oligodendrocytes ([@bib3]; [@bib39]). Although it is not clear why remyelination fails to occur in chronic demyelination ([@bib9]), the relative kinetics of vascular barrier disruption and remyelination suggest that it is possible that peripheral tissue--derived factors play an important supportive role during remyelination when the integrity of the BBB is impaired, such as during the remission phase of MS.

In this context, we identified circulating TGF-β1 as a candidate factor that promotes oligodendrocyte maturation. TGF-β1 does not cross the intact BBB ([@bib18]) and TGF-β1 concentration in the CSF is maintained at a lower level than that which is in the plasma of a healthy subject ([@bib35]). However, it is important to note that TGF-β1 is also expressed in CNS cells, including astrocytes. In MS, TGF-β1 expression is detected in the lesions ([@bib7]), and TGF-β1 mRNA expression in the spinal cord increased in advance of remission of EAE ([@bib16]). Since astrocyte-derived TGF-β1 regulates the local inflammatory response which contributes to the initiation of EAE ([@bib26]), CNS-cell-mediated TGF-β1 signaling may be involved in remyelination. However, TGF-β1 promotes Jagged1 expression in demyelinated lesions, and this upregulation inhibits oligodendrocyte maturation ([@bib17]), opposing the pro-remyelination effect of circulating TGF-β1. In addition, we found that oligodendrocyte maturation was detected in cells that were cultured in the presence of TGF-β1 at a concentration 29-fold higher than that of the CSF ([Figure 1H,I](#fig1){ref-type="fig"}). These data support our hypothesis that circulating TGF-β1 enters the CNS, and potentially contributes to remyelination.

This study resolves a long-standing debate about the therapeutic mechanism by which systemic TGF-β1 acts in the treatment of EAE and reveals the capacity of circulating TGF-β1 to contribute to the regeneration of neuronal networks after injury. Our study is currently limited to remyelination in MS. However, CNS regeneration is essential for efficient functional recovery after inflammation and injury in general. Therefore, our study predicts a new direction in CNS regeneration research with respect to the contribution of circulating factor in regeneration, which is supported by the previous findings that plastic changes of neuronal networks depend upon the systemic milieu ([@bib31]; [@bib36]; [@bib37]). In other contextual studies, it has been suggested that levels of circulating Growth differentiation factor 11, which belongs to the TGF-β family, decline with age and is linked to age-related systemic impairments such as cardiac hypertrophy ([@bib25]), skeletal muscle dysfunction ([@bib34]), and decline of neurogenesis in the subventricular zone ([@bib19]). These studies emphasize that circulating factors should be regarded as important molecular regulators of mammalian aging and have potentially broad-reaching implications.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Designation                                                                                               Source or reference                                              Identifiers                                                      Additional information
  --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------
  Tg(Plp1-cre/ERT)3Pop                                                                                      PMID:[12481300](https://www.ncbi.nlm.nih.gov/pubmed/12481300)    RRID:[MGI:3696409](https://scicrunch.org/resolver/MGI:3696409)   

  ALK5 flox                                                                                                 PMID:[12842983](https://www.ncbi.nlm.nih.gov/pubmed/12842983)                                                                     Dr. Stefan Karlsson (Lund University)

  Myelin Basic\                                                                                             PMID:[20209960](https://www.ncbi.nlm.nih.gov/pubmed/20209960)    RRID:[AB_305869](https://scicrunch.org/resolver/AB_305869)       IHC (1:500)
  Protein antibody                                                                                                                                                                                                                            

  Goat Anti-Human Olig2 Polyclonal antibody                                                                 PMID:[18615534](https://www.ncbi.nlm.nih.gov/pubmed/18615534)    RRID:[AB_2157554](https://scicrunch.org/resolver/AB_2157554)     IHC (1:300)

  Anti-APC (Ab-7) Mouse mAb (CC-1) antibody                                                                 PMID:[16705673](https://www.ncbi.nlm.nih.gov/pubmed/16705673)    RRID:[AB_2057371](https://scicrunch.org/resolver/AB_2057371)     IHC (1:500)

  Donkey Anti-Mouse IgG (H + L) Antibody,\                                                                  PMID:[23970788](https://www.ncbi.nlm.nih.gov/pubmed/23970788)    RRID:[AB_141633](https://scicrunch.org/resolver/AB_141633)       IHC (1:500)
  Alexa Fluor 594\                                                                                                                                                                                                                            
  Conjugated                                                                                                                                                                                                                                  

  Donkey Anti-Goat IgG (H + L) Antibody\                                                                    PMID:[25505326](https://www.ncbi.nlm.nih.gov/pubmed/25505326)    RRID:[AB_141844](https://scicrunch.org/resolver/AB_141844)       IHC (1:500)
  , Alexa Fluor 647 Conjugated                                                                                                                                                                                                                

  Phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) (D27F4) Rabbit mAb antibody                                 PMID:[28324027](https://www.ncbi.nlm.nih.gov/pubmed/28324027)    RRID:[AB_2631089](https://scicrunch.org/resolver/AB_2631089)     WB (1:1000)

  Smad2/3 (D7G7) XP Rabbit mAb antibody                                                                     PMID:[29056512](https://www.ncbi.nlm.nih.gov/pubmed/29056512)    RRID:[AB_10889933](https://scicrunch.org/resolver/AB_10889933)   WB (1:1000)

  Anti-Rabbit IgG Phototope-HRP Western Blot Detection System Antibody, Horseradish Peroxidase Conjugated                                                                    RRID:[AB_2099234](https://scicrunch.org/resolver/AB_2099234)     WB (1:2000)

  Rat Anti-CD41 Monoclonal Antibody, Unconjugated, Clone MWReg30                                            PMID:[30590031](https://www.ncbi.nlm.nih.gov/pubmed/30590031)    RRID:[AB_395084](https://scicrunch.org/resolver/AB_395084)       

  Goat Anti-Mouse Pdgf r alpha Polyclonal antibody, Unconjugated                                            PMID:[28111199](https://www.ncbi.nlm.nih.gov/pubmed/28111199)    RRID:[AB_2236897](https://scicrunch.org/resolver/AB_2236897)     IHC (1:500)

  TGFbeta RI (V-22) antibody                                                                                PMID:[29161592](https://www.ncbi.nlm.nih.gov/pubmed/29161592)    RRID:[AB_632493](https://scicrunch.org/resolver/AB_632493)       IHC (1:50)

  Donkey Anti-Rat IgG (H + L) Antibody, Alexa Fluor 488 Conjugated                                          PMID:[28280459](https://www.ncbi.nlm.nih.gov/pubmed/28280459)    RRID:[AB_141709](https://scicrunch.org/resolver/AB_141709)       IHC (1:500)

  TGF-beta 1,--2,−3 MAb (Clone 1D11) antibody                                                               PMID: [28521131](https://www.ncbi.nlm.nih.gov/pubmed/28521131)   RRID:[AB_357931](https://scicrunch.org/resolver/AB_357931)       

  Q-Plex Mouse Cytokine - Screen\                                                                           Quansys Biosciences                                              Cat. \#110949 MS                                                 
  (16-Plex)                                                                                                                                                                                                                                   

  Human\                                                                                                    Millipore                                                        Cat. \#CS204496                                                  
  Oligodendrocyte\                                                                                                                                                                                                                            
  differentiation Kit                                                                                                                                                                                                                         

  Human recombinant TGF-β1                                                                                  R and D Systems                                                  Cat. \#240-B                                                     

  Recombinant Murine basic FGF                                                                              Peprotech                                                        Cat. \#450--33                                                   

  Recombinant Murine PDGF-AA                                                                                Peprotech                                                        Cat. \#315--17                                                   

  LY364947                                                                                                  Calbiochem                                                       Cat. \#616451                                                    

  Recombinant mouse TGF-b1                                                                                  R and D Systems                                                  Cat. \#7666 MB-005                                               

  Mouse/Rat/Porcine/Canine TGFb1 Quantikine ELISA                                                           R and D Systems                                                  Cat. \#MB100B                                                    

  Cell Proliferation ELISA, BrdU (colorimetric)                                                             Sigma Aldrich                                                    Cat. \#11647229001                                               

  L-α-Lysophosphatidylcholine (LPC) from bovine brain                                                       Sigma Aldrich                                                    Cat. \#L1381                                                     

  InhibitorSelect 384-Well Protein Kinase Inhibitor Library I                                               Calbiochem                                                       Cat. \#539743                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

All experimental procedures were approved by the Institutional Animal Care Committee of Osaka University (no. 24-067-055) and the Committee on the Ethics of Animal Experiments of the National Institutes of Neuroscience, National Center of Neurology and Psychiatry (no. 2018042R5). C57BL/6J mice were obtained from Charles River Japan or Japan SLC. Plp-CreERT mice (C57BL/6 background) were purchased from the Jackson Laboratory. TGF-βRI (ALK5) floxed mice (C57BL/6 background) ([@bib23]) were kindly provided by Prof. Stefan Karlsson (Lund University). Mice were born and held in the specific pathogen free (SPF) conditions. Mice were housed in an air-conditioned room at 23 ± 1°C with a 12 hr light--dark cycle and had free access to water and food.

Oligodendrocyte-specific TGFβRΙ deletion mice were obtained by crossing the TGFβRΙ floxed mice with the Plp-CreERT mice. Cre recombination in the mice thus generated was induced by administering 4-hydroxytamoxifen (1 mg/kg/day, i.p.; Sigma-Aldrich, dissolved in dimethylsulphoxide (DMSO): ethanol: corn oil \[4:6:90\] mixture) daily over five consecutive days. Tamoxifen administration was started 7 days before LPC injection. TGF-βRI deletion in APC-labeled oligodendrocytes was immunohistochemically confirmed on the spinal cord tissues 14 days after LPC injection. In all cases, the experimenter was blinded to the origin of the samples. Mice were randomly allocated into groups.

Serum and plasma collection {#s4-2}
---------------------------

Cardiac blood was collected from 8 week old female C57BL/6J mice. For serum preparation, blood was collected and incubated for 30 min at room temperature, and then samples were centrifuged at 2000 × *g* for 15 min. The supernatant (serum) was collected and stored at −80°C. For plasma preparation, blood was collected using a heparin coated capillary (TERUMO) or an EDTA coated capillary (Vitrex Medical A/S). Samples were centrifuged at 2000 × *g* for 15 min. The supernatant (plasma) was collected and stored at −80°C.

For digestion experiments, serum was incubated at 37°C for 2 hr with 50 μg/ml DNase (Sigma, DN25) or 1 μg/ml RNase (Roche) at 37°C for 1 hr. For heat treatment, the serum was heated at 95°C for 5 min.

Primary culture of oligodendrocytes {#s4-3}
-----------------------------------

Oligodendrocytes were obtained from postnatal day 1 mice. The cerebral cortices were dissected in phosphate buffer saline (PBS) and dissociated into single-cell suspensions using the 0.25% Trypsin-PBS by incubation at 37°C for 15 min. After neutralization by Dulbecco\'s modified Eagles medium (DMEM) containing 10% fetal bovine serum (FBS), cells were centrifuged at 300 × *g* for 5 min, suspended in 10% FBS-DMEM, and filtered through a 70-µm nylon cell strainer. Single cells were plated at a density of 3--6 × 10^5^ cells/ml on poly-L-lysine (PLL)--coated dishes (Greiner Bio-One) and maintained at 37°C with 7% CO~2~ in 10% FBS-DMEM. Ten days after culturing, cells were washed in PBS. The remaining cells were treated with 0.05% Trypsin-PBS at 35°C for 4 min, and then tapped gently. The detached cells were filtered through a 40 µm nylon cell strainer and plated into non-coated dishes. After a 30-min incubation at 37°C, non-adherent cells were collected and plated at a density of 3 × 10^4^ cells/well into PLL-coated 96-well plates in OPC medium. OPC medium was constituted as follows: DMEM contained 4 mM L-glutamine (Sigma), 1 mM sodium pyruvate (Sigma), 0.1% bovine serum albumin (BSA; minimum 98% electrophoresis grade, Sigma), 50 μg/ml apo-transferrin (Sigma), 5 μg/ml insulin (Sigma), 30 nM sodium selenite (Sigma), 10 nM biotin (Sigma), 10 nM hydrocortisone (Sigma), 10 ng/ml platelet-derived growth factor-AA (PDGF-AA; Pepro Tech), and 10 ng/ml basic fibroblast growth factor (basic-FGF, Pepro Tech). Immunocytochemistry revealed that 58.1 ± 0.9% of the cells in the culture were co-labeled with Olig2, an oligodendrocyte marker (data not shown).

After 3 days of culturing, we performed pharmacological screening. The following drugs were used: Inhibitor Select 384-well Protein Kinase Inhibitory Library I (1:1000, Calbiochem), LY364947 (a transforming growth factor \[TGF\]-β receptor I \[TGF-βRI\] kinase inhibitor) (1 μM, Calbiochem), and recombinant mouse TGF-β1 (0.1--10 ng/ml, R and D Systems). Cells were cultured for an additional 5 days and used for evaluation in a differentiation assay.

siRNA transfections {#s4-4}
-------------------

Mouse TGF-βRI siRNA (ID: s75059) were purchased from Ambion. Transfection of cultured oligodendrocytes with TGF-βRI siRNA was performed using Lipofectamine RNAiMAX (Invitrogen). Cells were lysed 3 days after transfection and evaluated the TGF-βRI mRNA level by real-time PCR.

Immunocytochemistry {#s4-5}
-------------------

Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 30 min at room temperature, followed by blocking with PBS containing 5% bovine serum albumin (BSA; minimum 98% electrophoresis grade, Sigma-Aldrich) and 0.1% Triton X-100 for 1 hr at room temperature. The cells were incubated with primary antibodies diluted in the blocking solution (PBS containing 5% BSA and 0.1% Triton X-100) overnight at 4°C. The following antibodies were used for primary antibodies: rat anti-myelin basic protein (MBP; 1:500, Abcam, AB7349), goat anti-Olig2 antibody (1:300, R and D Systems, AF2418), and mouse anti-mouse APC (ab-7) (CC1; 1:500, Calbiochem, OP80). As secondary antibodies, the cells were incubated for 1 hr at room temperature with Alexa Fluor 488--conjugated donkey antibody against rat IgG, Alexa Fluor 594--conjugated donkey antibody against mouse IgG, or Alexa Fluor 647--conjugated donkey antibody against goat IgG (1:500, Invitrogen). The nuclei were stained with 4\',6-Diamidino-2-Phenylindole (DAPI, 1 μg/ml, Dojindo Laboratories) for 10 min. Images were acquired by fluorescence (Olympus BX53, 44FL).

To evaluate oligodendrocyte maturation, images were acquired with an IN Cell Analyzer 6000 (GE Healthcare) and quantified MBP^+^ area/Olig2^+^ cells to estimate oligodendrocyte differentiation using IN Cell developer (GE Healthcare).

Western blot analysis {#s4-6}
---------------------

Cells were homogenized in 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton-X 100, and 1 mM ethylenediaminetetraacetic acid (EDTA) containing protease inhibitor (Roche). The lysates were clarified by centrifugation at 8000 *g* at 4°C for 20 min, and the supernatants were collected and normalized for protein concentration. Proteins were separated by 10% sodium dodecyl sulfate--polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride membranes (Immobilon-P, Millipore). After blocking with PBS containing 5% skim milk and 0.05% Tween 20, the membranes were incubated with primary antibodies overnight at 4°C, followed by incubation with a fluorescently-labeled secondary antibody for 1 hr at room temperature. The following antibodies were used: rabbit anti-phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) (8828, Cell Signaling Technology) and rabbit anti-Smad2/3 (D7G7) (8685, Cell Signaling Technology). Horseradish peroxidase--conjugated anti-rabbit IgG antibody was used as secondary antibody (Cell Signaling Technology).

Immunoreactive bands were detected using a fluorescence-conjugated secondary antibody and an enhanced chemiluminescence (ECL) system (WBKLS0100, Millipore), and visualized on a LAS-4000 imaging system (Fujifilm). The protein bands were quantified using the ImageJ software.

Enzyme-linked immunosorbent assay (ELISA) {#s4-7}
-----------------------------------------

TGFβ levels in mouse serum, cerebrospinal fluid (CSF), or tissue lysates were examined using a Mouse/Rat/Porcine/Canine TGFβ1 Quantikine ELISA (R and D Systems). CSF was collected by cisterna magna puncture using 29-gauge needle. Mouse tissues were lysed in 5 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.02% sodium aside, 0.1% Triton-X, and protease inhibitor (Complete; Roche).

Surgical procedure {#s4-8}
------------------

Female mice (8--10 weeks old) were anesthetized with a mixture of Dormicam, 4 mg/kg; Vetorphale, 5 mg/kg; Domitor 4 mg/kg. The mice underwent laminectomy at Th12 and received injections of 2 µl of 1% (w/v) LPC dissolved in PBS into the dorsal column midline at a depth of 0.5 mm.

For administration of pharmacological reagent, an Alzet osmotic pump (model no. 1002; Alzet Corp) was filled with LY364847 (7.25 μg/kg of body weight per day). The pump was connected to a delivery tube, which was placed close to the site of the lesion 3 days after LPC injection. The pump was implanted subcutaneously on the back of the animal.

For administration of TGF-β neutralizing antibodies, TGF-beta 1, 2, 3 Antibody (R and D system) was intraperitoneally injected every 2 days (10 mg/kg of body weight per one injection). Administration of antibodies was stared 7 days after LPC injection. Control IgG was used for control experiments.

Platelet depletion {#s4-9}
------------------

Mice were intraperitoneally administered with rat anti-CD41 mAbs (BD Biosciences, 553847) or rat IgG1 control (BD Biosciences, 553922) for seven consecutive days from 7 days after LPC injection (10 μg/mouse on the first day, followed by 5 μg/mouse on following days). Platelet depletion was confirmed by flow cytometry with an FITC rat anti-mouse CD41 antibody (1:200, BD Pharmingen, 553848) on BD FACS Verse instrument.

Demyelination by cuprizone diet {#s4-10}
-------------------------------

Mice were fed with 0.2% (w/w) cuprizone (Sigma, C9012) for 12 weeks and then returned to a normal diet. Mice were maintained in sterile, pathogen-free conditions. For intraventricular administration of recombinant TGF-β1, an Alzet osmotic pump (model no. 1002; Alzet Corp) was filled with recombinant mouse TGF-β1 (266.5 μg/kg of body weight per day) and stereotactically equipped with a cannula (Brain Infusion Kit 3, ALZET Cupertino, 0008851) targeting the lateral ventricle of the brain (coordinate to bregma: anterior, 0.5 mm, lateral, −1.1 mm; ventral, 2.5 mm).

Histological analysis {#s4-11}
---------------------

Mice were transcardially perfused with PBS followed by 4% PFA in PBS. Brain and spinal cord were post-fixed with 4% PFA in PBS overnight at 4°C following immersion in 30% sucrose in PBS. Tissues were embedded in optimal cutting temperature compound (Tissue-Tek, Sakura Finetek USA Inc), and then 30 μm sections were cut and mounted on Matsunami adhesive silane-coated slides (Matsunami Glass). The sections were permeabilized with PBS containing 0.1% Triton X-100% and 3% normal donkey serum for 1 hr at room temperature. The sections were then incubated with primary antibodies overnight at 4°C, and then incubated with fluorescently labeled secondary antibodies for 1 hr at room temperature. The primary antibodies used were as follows: goat anti-mouse PDGFRα (1:500, R and D Systems, AF1062), rabbit anti-human TGF-βRI (V-22) (1:50, Santa Cruz Biotechnology, SC-398), mouse anti-mouse APC (ab-7) (CC1; 1:500, Calbiochem, OP80), rat anti-myelin basic protein (MBP; 1:500, Abcam, AB7349). Secondary antibodies were Alexa Fluor 488-, 568-, and 594-conjugated antibodies produced in donkey (1:500 in PBS with 0.05% Tween-20 \[Sigma\]; Invitrogen). Nuclear staining was performed with 1 μg/ml DAPI. Images were acquired by fluorescence (Olympus BX53, 44FL) or confocal laser-scanning microscopy (Olympus FluoView FV1200).

To evaluate remyelination, MBP negative area in the dorsal column of the spinal cord was measured by Image J software. The mean was calculated from at least 10 sections spaced 100 μm apart.

To evaluate inflammation index, sections were stained by hematoxylin and eosin. The number of inflammatory foci, which reflects an accumulation of immune cells, were counted in the sections and were normalized to the area per mm².

Electron microscopy {#s4-12}
-------------------

Mice were transcardially perfused with ice-cold PBS followed by a fixative (2% paraformaldehyde in PBS). Spinal cord tissues were removed and postfixed in the same fixative at 4°C overnight. Spinal cords were sliced into 50 μm pieces using a Vibrating Blade Microtome and washed in 0.1 M PB to prepare the sample for electron microscopy at Hanaichi UltraStructure Research Institute. Samples were observed by transmission electron microscopy (H-7650, Hitachi). The g-ratio was calculated by dividing the diameter of the inner axon by the diameter of the myelinated fiber.

Beam walking test {#s4-13}
-----------------

Mice were pre-trained 2 days before test. A recording was made of mice walking on a wooden beam (1.05 m length, 10 mm width, Beam test experimental device \[Brain Science Idea Co. Ltd., cat. no. BS-VAM\]). Every footstep of each hindlimb was scored according to the following criteria: 0 = normal, no footslip; 1 = mild footslip, in which a part of foot is seen below the surface of the beam; 2 = severe footslip, in which whole foot is seen below the surface of the beam. Total scores were created by summing up the individual scores. The data was obtained by taking the average of three trials per beam per mouse.

EAE induction {#s4-14}
-------------

Female mice were immunized by subcutaneous injection of 200 μl emulsion (100 μg MOG~35--55~ peptide \[MEVGWYRSPFSRVVHLYRNGK, Sigma-Aldrich\] in complete Freund's adjuvant emulsion \[CFA, Difco\] containing 500 μg *Mycobacterium tuberculosis H37Ra* \[Difco\]). Mice were injected 100 ng pertussis toxin (List Biological Laboratories) intravenously 0 hr and 48 hr after immunization. The mice were assessed for signs of EAE according to the following scale: 0, no clinical signs; 0.5, tail tip droop; 1, partially tail droop; 1.5, tail paralysis; 2.0, hindlimb weakness; 2.5, one hindlimb paralysis; 3.0, both hindlimb paralysis; 3.5, hindlimb paralysis and forelimb weakness; 4.0, hindlimb paralysis and one forelimb paralysis; 4.5, hindlimb paralysis and both forelimb paralysis; 5.0, moribund or death.

To investigate the therapeutic role of TGF-β1 on EAE, intravenous injection of recombinant TGF-β1 (5 μg/kg of body weight per day) was started at 15 days after immunization and continued for up to 10 additional days.

Splenocyte culture {#s4-15}
------------------

Splenocytes were collected from mouse spleen 21 days after EAE induction. Spleen were dissected and triturated by using 1-ml syringe and 100-µm nylon cell strainer in RPMI1640 (Sigma), and then cells were treated with hemolysis buffer (Immuno-Biological Laboratories). After centrifugation, cells were suspended in RPMI1640 containing 10 mM HEPES buffer (Sigma), 10% FBS, 50 μM 2-mercaptoethanol, and penicillin-streptomycin (Gibco). Cells were cells were plated at density of 1 × 10^4^ cells/well into 96-well plates and were maintained at 37°C with 5% CO~2~. To evaluate cell proliferation, cells were cultured with 20 μg/mL MOG~35-55~ peptide for 72 hr. Cell proliferation was assessed using the Cell Proliferation ELISA and BrdU (colorimetric) kit (Sigma). BrdU solution was added into the culture 24 hr before the end of culturing. To evaluate the cytokine release, cells were cultured with 20 μg/mL MOG~35-55~ peptide for 72 hr. The supernatants of the culture were collected and were used for the analysis of cytokine level by Q--Plex array (Quansys Biosciences).

Human oligodendrocyte culture {#s4-16}
-----------------------------

Human oligodendrocytes (Human Oligodendrocyte differentiation Kit; Millipore, CS204496) were cultured in the Human OPC Expansion Complete Media (Millipore). After seven days of culture, the cells were re-plated at a density of 5 × 10^4^ cells/well in 24-well plates in Human OPC Expansion Complete Media. Cells were treated with human recombinant TGF-β1 (0.1--10 ng/ml, R and D Systems) for 3 days. After culturing, the cells were used for real-time PCR analysis. Immunocytochemistry revealed that 97.68 ± 1.2% of DAPI^+^ cells in the culture were co-labeled with Olig2, an oligodendrocyte marker (data not shown).

Immunohistochemistry of human tissue {#s4-17}
------------------------------------

We obtained autopsied spinal cord tissues from four healthy individuals (three men; median age: 68 years; range: 63--70 years) and three individuals with multiple sclerosis (one man; median age: 66 years; range: 63--85 years). Formalin-fixed spinal cord samples were embedded in paraffin and cut into 10-μm-thick sections for immunohistochemistry. The sections were deparaffinized and treated with 5% BSA and 0.3% Triton X-100 in PBS for 1 hr at room temperature. The sections were incubated with primary antibodies for 24 hr at 4°C and then incubated with secondary antibodies for 1 hr at room temperature. Primary antibodies were rabbit anti-human TGF-βRI (V-22) (1:50, Santa Cruz Biotechnology, SC-398) and mouse anti-APC (CC1; 1:20, Calbiochem). Secondary antibodies were Alexa Fluor 488- and 594- conjugated antibodies produced in donkey (1:500; Invitrogen). Nuclear staining was performed with 1 μg/ml DAPI. Images were acquired by confocal laser-scanning microscopy (Olympus FluoView FV1200). The research protocol was approved by the Human Use Review Committees of Toneyama National Hospital (TNH-2018031). Informed consent was obtained from all subjects.

Quantitative RT-PCR {#s4-18}
-------------------

Total RNA was isolated using the RNeasy Mini kit (Qiagen), and cDNA was synthesized using the PrimeScript II High Fidelity RT-PCR Kit (Takara Bio Inc). cDNA fragments were amplified using the following primer pairs: mouse TGF-β1 forward, GGACTCTCCACCTGCAAGAC; mouse TGF-β1 reverse, GACTGGCGAGCCTTAGTTTG; mouse TGFβ receptor type I forward, TGCCATAACCGCACTGTCA; mouse TGFβ receptor type I reverse, AATGAAAGGGCGATCTAGTGATG; mouse GAPDH forward, TGTGTCCGTCGTGGATCTGA; mouse GAPDH reverse, TTGCTGTTGAAGTCGCAGGAG; human MBP forward, GGCCTTACCACTCGGTGATTAT; human MBP reverse, TTTCTGCAAAGGACTCTGTGAAGA; human PLP forward, CCATGCCTTCCAGTATGTCATC; human PLP reverse, GCCCTCAGCCAGCAGGA; human MOG forward, TTGTGTGAGTGCCTGGCAA; human MOG reverse, TGCCTCCACTCCGGTAATTG; human GAPDH forward, AGGGCTGCTTTTAACTCTGGT, human GAPDH reverse, CCCCACTTGATTTTGGAGGGA. Samples for SYBR Green assays consisted of a 1 × final concentration of Power SYBR Green PCR Master Mix (Applied Biosystems, 4385612), 200 nM gene-specific primers, and 10 ng cDNA. PCR conditions included one cycle at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s (ABI ViiA7 real-time PCR system; Applied Biosystems). A melting temperature analysis was carried out following PCR to monitor amplification specificity. Relative mRNA expression was normalized against GAPDH mRNA levels in the same samples and calculated by the ∆/∆-Ct method.

Statistical analysis {#s4-19}
--------------------

Data are presented as mean ± SEM. Statistical significance between groups was determined by unpaired Student's *t*-test, paired *t*-test, or repeated-measures ANOVA followed by post-hoc comparison with Dunnett\'s test or Tukey-Kramer test. p\<0.05 was considered to represent a significant difference.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"Circulating transforming growth factor-beta1 facilitates remyelination in the adult central nervous system\" for peer review at *eLife*. Your article is being evaluated by 3 peer reviewers, and the evaluation is being overseen by a guest Reviewing Editor and Didier Stainier as the Senior Editor.

Particular emphasis should be placed on experiments that provide direct evidence for a specific role of circulating transforming growth factor-beta1 in remyelination.

*Reviewer \#1:*

Summary:

In this article Hamaguchi et al. aim to investigate the potential role of circulating factors, specifically TGF-β1, in the maturation of oligodendrocyte lineage cells for the promotion of remyelination in the central nervous system. The authors demonstrate that serum stimulation facilitates the maturation of oligodendrocytes, and TGF-β1 signaling, in particular, is required for serum-induced maturation. The authors report that both circulating TGF-β1 and TGF-βRI in oligodendrocyte lineage cells are required for normal spontaneous remyelination following LPC-induced demyelination. Additionally, TGF-β1 administration, by both cerebroventricular and intravenous injection, was demonstrated to promote remyelination in two complementary models of demyelination. The authors also report that human oligodendrocytes express TGF-βRI and stimulation of human oligodendrocyte cultures with recombinant TGF-β1 promotes the expression of myelin-associated genes. Hamaguchi et al. conclude that the administration of systemic TGF-β1 may hold therapeutic potential for treating demyelinating diseases by entering the CNS in conditions of increased blood brain barrier permeabilization. While the authors provide strong support for a role of TGF-β1 signaling in remyelination, their current evidence does not directly show that the therapeutic effect of circulating TGF-β1 requires entry into the CNS for the promotion of oligodendrocyte maturation.

Essential revisions:

1\) This study builds upon previous evidence for the therapeutic potential of TGF-β1 in demyelinating diseases, but it does not fully resolve the long-standing debate about the therapeutic mechanism of TGF-β1 in demyelinating diseases as it claims. The authors provide strong evidence for TGF-β1 signaling promoting oligodendrocyte maturation, but the authors do not account for the influence of TGF-β1 on regulatory T cells in recovery from demyelination. To determine the therapeutic mechanism of circulating TGF-β1, authors should provide a direct link between the therapeutic effect of systemic administration of TGF-β1 and oligodendrocyte expressed TGF-βRI. To establish the therapeutic mechanisms of circulating TGF-β1, authors likely need to systemically administer TGF-β1 to mice with conditional deletion of TGF-βRI in oligodendrocytes following LPC-induced demyelination. Provided systemic administration of TGF-β1 has no therapeutic effect in mice lacking TGF-βRI in oligodendrocytes, authors may conclude that CNS entry of circulating TGF-β1 is required to promote remyelination.

2\) A weakness of the present study is the use of anti-CD41-induced platelet depletion as the sole method for reducing circulating TGF-β1. The authors determine that depletion of platelets reduces circulating TGF-β1, but they do not account for altering other platelet-dependent effects on remyelination. An additional tool to reduce circulating TGF-β1 is required prior to concluding that circulating TGF-β1 is critical in remyelination.

*Reviewer \#2:*

In the manuscript \"Circulating transforming growth factor-β 1 facilitates remyelination in the adult central nervous system\", Hamaguchi et al. describe the role of TGFbeta 1 on promoting oligodendrocyte differentiation and remyelination. The role of TGFbeta1 in these processes have previously been established, and the authors present data that indeed confirms the role of TGF-beta1 on oligodendrocyte maturation and remyelination. The authors suggest that circulating TGF-beta1 is important in remyelination, which would be a very interesting observation. Unfortunately, I don\'t consider that the data on the current manuscript is conclusive and the authors would need to provide much further substantiation for this hypothesis.

Essential revisions:

\- The authors embark in a pharmacological screen, but the screen is barely mentioned in the results or methods. The authors need to describe the screen in much more detail. Also, it is not clear what is the rationale for focusing on TGF-beta1 rather than other pathways that appear to have a much more robust effect. Finally, the supplement table 1 is very poorly described, it is not clear what which column refers to, the authors need to explain properly this table.

\- The authors deplete platelets using anti-CD41 antibodies and observe a reduction of MBP staining 14 days after LPC injection:

\- Depletion of the platelets will most likely not only affect the transport of TGF-beta1, but also of other factors as VEGF, among others. As such, the authors cannot ascribe the effects only to TGF-beta1. A regain of function experiment, such as intracerebroventricular infusion of TGF-beta1 in a platelet depletion paradigm and upon PLC injection, would be able to validate the authors\' hypothesis.

\- The authors should validate the reduction of the levels of TGF-beta1 protein at the lesion, as in Figure 2C

\- When referring to the decrease in MBP staining in the lesions, the authors often mention \"demyelination area\". One of the advantages of the LPC experimental setup is that one can differentiate demyelination from remyelination, as they are temporally separated in this paradigm. Since the authors are evaluating 14 days after LPC, they are most likely assessing remyelination. If they want to assess demyelination, they should assess earlier time points. The authors should revise their conclusions throughout the text and I would advise adding schemes of the experimental setup for data collection after LPC, so it is clear what outcome they are assessing.

\- The inducible KO of TGF-beta1 receptor approach in Figure 4B-D reinforces the role of TGF-β 1 in remyelination, but does not address the role of circulating TGF-beta1, which would be the major novelty of the paper.

\- The effects on systemic TGF-beta1 in EAE are interesting, but are modest, it is not clear whether the changes in MBP is due to effects on demyelination or remyelination, which is particularly relevant given that it has been shown that TGF-beta1 has an effect on immune cells in the context of EAE (Lee et al., 2015, among others).The authors should do a more thorough analysis on the putative effects of TGF-beta1 on the immune system in their paradigm, in order to be able to rule out that these are not the main mediators of the effects observed.

*Reviewer \#3:*

Oligodendrocyte maturation is necessary for functional regeneration in the CNS. The authors show that TGF-beta1 is present in higher levels in the peripheral environment and promotes oligodendrocyte maturation. They show decreasing circulating TGF-β1 level reduces remyelination in the spinal cord in a toxin-induced demyelination model. TGF-β1 administration promotes remyelination and restored neurological function in a multiple sclerosis animal model. In addition, they show TGF- beta1 stimulates maturation of human oligodendrocyte in vitro.

The role of TGF-beta1 in oligodendrocyte differentiation and maturation has been well studied. The protective effects of TGF-beta1 has also been reported. The novel findings of this manuscript are that the circulating TGF-beta1 promotes oligodendrocyte maturation and facilitates remyelination. The experiments are overall well designed.

An important concern about the paper is how specific are the findings to oligodendrocytes and whether the behavioral deficits observed can be attributed only to oligodendrocyte maturation. I have the following comments:

Figure 1. To show TGF-beta1 enhances oligodendrocyte maturation directly, they authors need to show that oligodendrocytes express the receptors of TGF-β and that TGF-β1 activates the signaling pathway in oligodendrocytes (for example increase of pSamd2,3 or downstream target gene expression).

Figure 2. It is interesting that the spleen has highest concentration of TGF-beta1, is it because the spleen produces more than other organs or because TGF-beta1 accumulates in the spleen?

In addition, some important data rely on quantitative analyses of immunostaining. It would improve the quality of the manuscript if those data would also be supported by an independent assay.

10.7554/eLife.41869.018

Author response

Reviewer \#1:

> \[...\] Essential revisions:
>
> 1\) This study builds upon previous evidence for the therapeutic potential of TGF-β1 in demyelinating diseases, but it does not fully resolve the long-standing debate about the therapeutic mechanism of TGF-β1 in demyelinating diseases as it claims. The authors provide strong evidence for TGF-β1 signaling promoting oligodendrocyte maturation, but the authors do not account for the influence of TGF-β1 on regulatory T cells in recovery from demyelination. To determine the therapeutic mechanism of circulating TGF-β1, authors should provide a direct link between the therapeutic effect of systemic administration of TGF-β1 and oligodendrocyte expressed TGF-βRI. To establish the therapeutic mechanisms of circulating TGF-β1, authors likely need to systemically administer TGF-β1 to mice with conditional deletion of TGF-βRI in oligodendrocytes following LPC-induced demyelination. Provided systemic administration of TGF-β1 has no therapeutic effect in mice lacking TGF-βRI in oligodendrocytes, authors may conclude that CNS entry of circulating TGF-β1 is required to promote remyelination.

According to the reviewer's suggestion, we injected LPC into the spinal cords of oligodendrocyte (OL)-specific TGF-βRI knockout mice (PLP-Cre::TGF-βRI flox) and treated the mice with recombinant mouse TGF-β1. Immunohistochemical analysis revealed that TGF-β1 treatment did not change the MBP-negative area in the spinal cord 2 weeks after LPC injection (Figure 4E,F), indicating that CNS entry of circulating TGF-β1 is required to promote remyelination. We added these results to subsection "TGF-βRI in oligodendrocytes is involved in spontaneous remyelination".

> 2\) A weakness of the present study is the use of anti-CD41-induced platelet depletion as the sole method for reducing circulating TGF-β1. The authors determine that depletion of platelets reduces circulating TGF-β1, but they do not account for altering other platelet-dependent effects on remyelination. An additional tool to reduce circulating TGF-β1 is required prior to concluding that circulating TGF-β1 is critical in remyelination.

We treated wild-type mice with TGF-β neutralizing antibodies and injected LPC into the mice spinal cords. We evaluated the demyelinated area by measuring the MBPnegative area in spinal cord sections. Immunohistochemical analysis revealed that mice treated with TGF-β neutralizing antibodies had a larger MBP-negative area than controls (i.e., mice subjected to control IgG treatment, Figure 3F,G), consistent with the results of the platelet depletion experiments (Figure 3B,C). We added the results in subsection "Circulating TGFβ-1 contributes to remyelination in the CNS".

Reviewer \#2:

> \[...\] Essential revisions:
>
> \- The authors embark in a pharmacological screen, but the screen is barely mentioned in the results or methods. The authors need to describe the screen in much more detail. Also, it is not clear what is the rationale for focusing on TGF-beta1 rather than other pathways that appear to have a much more robust effect. Finally, the supplement table 1 is very poorly described, it is not clear what which column refers to, the authors need to explain properly this table.

Thank you for this feedback. We screened 160 drugs and found 107 drugs (blue area Panel 1 of [Author response image 1](#respfig1){ref-type="fig"}) that did not decrease the abundance of Olig2positive cells (0.5 times lower than control) in the culture after each treatment. We next excluded the drugs that decreased MBP expression (0.5 times lower than control) in the cells by drug treatment or serum treatment (without drug), and identified 17 drugs (please see orange area Panel 2 of [Author response image 1](#respfig1){ref-type="fig"}) that downregulated MBP area (2 times lower than control) relative to cells subjected to serum treatment. In this experiment, we searched for a circulating molecule that drives oligodendrocyte maturation directly; therefore, we focused on the TGF-β receptor type I inhibitor (TGF-βRI), the only drug we tested that specifically targets a receptor-type protein. We added this description to the Results section. We also revised Figure 1---source data 1 and the figure legend of source data 1.

![](elife-41869-resp-fig1){#respfig1}

> \- The authors deplete platelets using anti-CD41 antibodies and observe a reduction of MBP staining 14 days after LPC injection:
>
> \- Depletion of the platelets will most likely not only affect the transport of TGF-beta1, but also of other factors as VEGF, among others. As such, the authors cannot ascribe the effects only to TGF-beta1. A regain of function experiment, such as intracerebroventricular infusion of TGF-beta1 in a platelet depletion paradigm and upon PLC injection, would be able to validate the authors\' hypothesis.

Thank you for this suggestion. We believe that the reviewer is asking us whether other platelet-derived factors are involved in remyelination. To answer this question, we must evaluate whether platelet-specific TGF-β1 depletion decreases remyelination efficiency after LPC injection. However, platelet-specific depletion is technically difficult because plateletspecific Cre mice are not available. Hence, as an alternative, we used neutralizing TGF-β1 antibodies. We found that TGF-β1 neutralization prevented remyelination after LPC injection (Figure 3F,G). In addition, we compared the inhibitory ratio of remyelination between TGF-β1 neutralization and platelet depletion, and found that they were comparable (*Pint* = 0.6126, single regression analysis), indicating that TGF-β1 makes a major contribution to remyelination mediated by circulating factors. We added this description in the Results section (Subsection "Circulating TGFβ-1 contributes to remyelination in the CNS").

> \- The authors should validate the reduction of the levels of TGF-beta1 protein at the lesion, as in Figure 2C.

We evaluated the intensity of the TGF-β1 signal around the LPC lesion in spinal cords from mice treated with or without CD41 antibodies. Immunohistochemical analysis revealed that mice treated with CD41 antibodies had lower levels of TGF-β1 than controls (Figure 3---figure supplement 1B,C), indicating that depletion of platelets decreased the level of TGF-β1 at the lesion. We added this description to the Results section (subsection "Circulating TGFβ-1 contributes to remyelination in the CNS").

> \- When referring to the decrease in MBP staining in the lesions, the authors often mention \"demyelination area\". One of the advantages of the LPC experimental setup is that one can differentiate demyelination from remyelination, as they are temporally separated in this paradigm. Since the authors are evaluating 14 days after LPC, they are most likely assessing remyelination. If they want to assess demyelination, they should assess earlier time points. The authors should revise their conclusions throughout the text and I would advice adding schemes of the experimental setup for data collection after LPC, so it is clear what outcome they are assessing.

Thank you for the suggestion. As reviewer \#2 might have expected, we did not focus on demyelination in this study. We emphasized our focus on remyelination in the Results section (subsection "Circulating TGFβ-1 contributes to remyelination in the CNS") and revised "demyelinated area" to "MBP negative area" in pertinent passages.

> \- The inducible KO of TGF-beta1 receptor approach in Figure 4B-D reinforces the role of TGF-β 1 in remyelination, but does not address the role of circulating TGF-beta1, which would be the major novelty of the paper.

To investigate the effect of circulating TGF-β1 on remyelination, we used TGF-β neutralizing antibodies and investigated whether TGF-β neutralization would prevent remyelination after LPC injection. Immunohistochemical analysis revealed that the MBPnegative area was higher in mice treated with TGF-β neutralizing antibodies than in controls (Figure 3F,G), consistent with results obtained using oligodendrocyte-specific TGF-βRI knockout mice (Figure 4B,C). This consistency in the data supports our conclusion that circulating TGF-β1 promotes spontaneous remyelination in this context.

> \- The effects on systemic TGF-beta1 in EAE are interesting, but are modest, it is not clear whether the changes in MBP is due to effects on demyelination or remyelination, which is particularly relevant given that it has been shown that TGF-beta1 has an effect on immune cells in the context of EAE (Lee et al., 2015, among others).The authors should do a more thorough analysis on the putative effects of TGF-beta1 on the immune system in their paradigm, in order to be able to rule out that these are not the main mediators of the effects observed.

According to the reviewer's suggestion, we investigated whether TGF-β1 regulates inflammatory responses, which are related to disease progression of EAE (Muramatsu et al., 2012). To this end, we collected lymphocytes and splenocytes from EAE mice and re-stimulated the cells with MOG~35-55~peptides in vitro. Evaluation of cytokine expression and cell proliferation activity revealed that TGF-β1 did not change the inflammatory response in our experimental contexts (Figure 5---figure supplement 1C,D). These data confirm our observation that TGF-β1-mediated remyelination does not depend on regulation of immunological response. We added this explanation to the Results section.

Reviewer \#3:

> \[...\] An important concern about the paper is how specific are the findings to oligodendrocytes and whether the behavioral deficits observed can be attributed only to oligodendrocyte maturation. I have the following comments:
>
> Figure 1. To show TGF-beta1 enhances oligodendrocyte maturation directly, they authors need to show that oligodendrocytes express the receptors of TGF-β and that TGF-β1 activates the signaling pathway in oligodendrocytes (for example increase of pSamd2,3 or downstream target gene expression).

Thank you for this suggestion. We investigated the expression of TGF-β1 receptor in the mouse oligodendrocyte culture. Immunocytochemical analysis revealed that APClabeled oligodendrocytes express TGF-β1 receptor. We provided a representative image in Figure 1J and revised the Results section accordingly. To determine whether TGFβ1 activates signaling pathway in oligodendrocytes, we stimulated mouse oligodendrocytes with recombinant TGF-β1 and evaluated phosphorylation of the Smad2 protein. Western blot analysis revealed an increase in Smad2 phosphorylation 30 mins after TGF-β1 treatment of oligodendrocytes (Figure 1---figure supplement 1F,G). We added this information to the Results section.

> Figure 2. It is interesting that the spleen has highest concentration of TGF-beta1, is it because the spleen produces more than other organs or because TGF-beta1 accumulates in the spleen?

To determine why the spleen had the highest concentration of TGF-β1, we depleted platelets in the mice by injecting CD41 antibodies, and then measuring the TGF-β1 level in the spleen. TGF-β1 levels in spleen were lower in mice subjected to platelet depletion than in controls (Figure 3---figure supplement 1A), suggesting that a high concentration of TGF-β1 in the spleen depends on platelet-mediated TGF-β1 accumulation in the spleen. We added this result on subsection "Circulating TGFβ-1 contributes to remyelination in the CNS".

> In addition, some important data rely on quantitative analyses of immunostaining. It would improve the quality of the manuscript if those data would also be supported by an independent assay.

According to the reviewer's suggestion, we performed electron microscopic analysis to determine whether our observation by immunostaining encompass structural remyelination. For this purpose, we injected platelet-depleted mice with LPC and found that the thickness of myelin sheaths was significantly lower in mice treated with anti-CD41 mAb than in controls (Figure 3D,E), indicating that our findings were also consistent with structural remyelination. We added this result on subsection "Circulating TGFβ-1 contributes to remyelination in the CNS". We appreciate the reviewer's suggestions because the additional experiments we performed in response to these comments have strengthened the core argument of this manuscript.
